EnBiotix
About
EnBiotix advances front-line labeled products for chronic, recurrent, and life-threatening pulmonary infections.
- Cambridge,Massachusetts,United States
- 1 - 10
Details
- Last Funding Type
- Convertable Note
- Last Funding Money Raised
- $11M
- Industries
- Biotechnology,Health Care,Pharmaceutical
- Founded date
- Jan 1, 2012
- Number Of Employee
- 1 - 10
- Operating Status
- Active
EnBiotix is a product-focused bioengineering company that advances front-line labeled products for chronic, recurrent, and life-threatening pulmonary infections. Through breakthrough systems and synthetic biology platforms, EnBiotix is transforming and revitalizing existing antibiotic classes to combat the global rise of drug-resistant bacterial infections. These approaches have developed a robust clinical product pipeline addressing a wide range of acute and chronic infections in what is today over a $40 billion market, with the potential to significantly impact the lives of patients, caregivers, and payors worldwide.It was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Apr 5, 2022 | Series Unknown | $3.46M | — | — | — | Detail |
| Dec 29, 2021 | Convertable Note | $11M | 3 |
Vectura Group
|
— | Detail |
| Sep 26, 2019 | Series Unknown | $3.14M | — | — | — | Detail |
| May 12, 2016 | Series A | — | 2 |
|
— | Detail |
| Jan 1, 2016 | Grant | — | — | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Vectura Group
|
Yes | Convertable Note |
|
|
Yes | Series A |
|
|
— | Convertable Note |
Cystic Fibrosis Foundation
|
— | Convertable Note |
|
|
— | Series A |
Employee Profiles
Acquisition
EnBiotix has acquired 1 organizations. Their most recent acquisition was AMP Therapeutics - Antimicrobial Peptides on Nov 3, 2016. They acquired AMP Therapeutics - Antimicrobial Peptides for 0.
|
Date
Company Name
|
Industry | Acquisition Type | Price | |
|---|---|---|---|---|
|
Nov 3, 2016
|
Alternative Medicine | acquisition | — | Detail |
